{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Acetylated-histone-H3 levels were obtained through bone marrow biopsies and measured using established methods. This analysis aimed to analyze the association between overall response and percent change of acetylated histone h3 in samples using a paired t-test.","groups":[{"description":"30 mg three days a week (Mondays, Wednesdays and Fridays).\n\n1 cycle was 28 days\n\nDose modifications for attributable toxicities allowed for reduction to:\n\n* 25 mg, 20 mg three times a week every week\n* Or 20 mg three times a week every other week. No dose re-escalation was allowed.\n\n  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.\n\nLBH589","id":"OG000","title":"LBH589"}],"populationDescription":"Only three complete sample (baseline and post-therapy) were ascertained. The difference in percentage of acetylated histone h3 were not large enough to conduct the correlative analysis.","reportingStatus":"POSTED","timeFrame":"Bone marrow biopsies were obtained at the start of treatment (baseline) and after the 6th cycle.","title":"Acetylated Histone H3 and Overall Response Association","type":"SECONDARY"}